Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell/Tumor Fusion Vaccine and IL-12 in Stage IV Breast Cancer
NCT00622401Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Dec 2009
- Primary completion
- Oct 2014
- Modality
- Whole Cell Cancer Vaccines, Cytokines & Interferons, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous dendritic cell-tumor fusion vaccine and recombinant interleukin-12 in breast cancer (3 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Number of Participants With Adverse Events Associated With Vaccination at 3 years. Started Dec 2009; status: terminated.
02
Drugs
autologous dendritic cell-tumor fusion vaccinerecombinant interleukin-12
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00622401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622401.